- Home
- TEM vs ITCI Comparison
TEM vs ITCI Comparison
Compare TEM & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEM
- ITCI
- Stock Information
- Founded
- TEM 2015
- ITCI 2002
- Country
- TEM United States
- ITCI United States
- Employees
- TEM N/A
- ITCI N/A
- Industry
- TEM
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- TEM
- ITCI Health Care
- Exchange
- TEM NYSE
- ITCI Nasdaq
- Market Cap
- TEM 6.3B
- ITCI 8.7B
- IPO Year
- TEM 2024
- ITCI N/A
- Fundamental
- Price
- TEM $31.83
- ITCI $126.89
- Analyst Decision
- TEM Buy
- ITCI Buy
- Analyst Count
- TEM 11
- ITCI 13
- Target Price
- TEM $57.20
- ITCI $100.31
- AVG Volume (30 Days)
- TEM 4.0M
- ITCI 2.9M
- Earning Date
- TEM 02-17-2025
- ITCI 02-20-2025
- Dividend Yield
- TEM N/A
- ITCI N/A
- EPS Growth
- TEM N/A
- ITCI N/A
- EPS
- TEM N/A
- ITCI N/A
- Revenue
- TEM $640,442,000.00
- ITCI $613,728,000.00
- Revenue This Year
- TEM $32.70
- ITCI $48.41
- Revenue Next Year
- TEM $38.77
- ITCI $38.26
- P/E Ratio
- TEM N/A
- ITCI N/A
- Revenue Growth
- TEM 32.13
- ITCI 46.08
- 52 Week Low
- TEM $22.89
- ITCI $62.78
- 52 Week High
- TEM $79.49
- ITCI $128.00
- Technical
- Relative Strength Index (RSI)
- TEM N/A
- ITCI 87.18
- Support Level
- TEM N/A
- ITCI $80.83
- Resistance Level
- TEM N/A
- ITCI $128.00
- Average True Range (ATR)
- TEM 0.00
- ITCI 2.57
- MACD
- TEM 0.00
- ITCI 4.45
- Stochastic Oscillator
- TEM 0.00
- ITCI 97.65
About TEM TEMPUS AI INC
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.